Johnson & Johnson: Can the Pipeline Actually Replace What Stelara Was?

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Johnson & Johnson typically reports earnings before the market opens, meaning Day 0 captures the first full trading session of reaction, while Day +1 reflects follow-through momentum.

Historically, JNJ has exhibited moderate volatility around earnings, with an average absolute Day 0 move of 1.86% and an average intraday range of 3.73%. The stock tends to see most of its price action on the day of the report, with Day +1 moves averaging just 0.51% and a tighter range of 1.80%—suggesting that the market digests the results quickly and follow-through is limited.

The most recent earnings cycle in April 2026 saw a modest 0.90% gain on Day 0, well below the historical average, indicating a muted reaction to what was likely an in-line or slightly positive result. In contrast, the July 2025 report triggered a sharp 6.19% rally—an outlier that likely reflected a significant positive surprise or bullish guidance. For the upcoming release, investors should expect a move in the 2% to 3% range based on historical patterns, though the elevated geopolitical uncertainty and recent oil price volatility could amplify reactions if results or guidance deviate meaningfully from expectations.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 2.90% by the July 17 expiration, slightly above the stock's average historical Day 0 move of 1.86% but well within the typical intraday range of 3.73%. This suggests options traders are anticipating a moderately elevated reaction—likely reflecting the combination of heightened macro uncertainty and the stock's recent run-up—but not an outsized swing relative to JNJ's historical earnings behavior.

Part 3: What Analysts Are Saying

Analysts remain firmly bullish on Johnson & Johnson, with the stock carrying an average recommendation of 4.16 out of 5.00—solidly in "Buy" territory. The consensus is supported by 13 Strong Buy ratings and 3 Moderate Buy ratings, while 9 analysts rate the stock a Hold. Notably, there are zero Sell or Strong Sell ratings, underscoring broad confidence in JNJ's defensive qualities and growth prospects.

Sentiment has been unchanged over the past month, with the rating distribution holding steady at the same levels. This stability suggests analysts are comfortable with their current views and see no immediate catalysts to shift their stance ahead of the earnings release. The lack of downgrades is particularly notable given the recent geopolitical volatility, indicating that analysts view JNJ's diversified business model and strong balance sheet as insulating factors.

The consensus price target sits at $262.56, implying roughly 3.4% upside from the current price of $253.85. The range of targets is wide, spanning from a low of $210.00 to a high of $298.00, reflecting differing views on the pace of pharmaceutical pipeline growth and the impact of currency headwinds. Still, the mean target suggests analysts see limited near-term upside, with most of the bullish case likely contingent on sustained earnings growth and successful new product launches over the next 12 to 18 months.

Part 4: Technical Picture

Johnson & Johnson enters earnings with a strong technical setup, supported by a Barchart Technical Opinion of 88% Buy—unchanged from last week but up sharply from 56% Buy a month ago. This improvement reflects the stock's recent rally and positive momentum heading into the release.

Timeframe Analysis:

• Short-term (100% Buy): A perfect buy signal indicates near-term momentum is decisively positive, with the stock in a clear uptrend over the past few weeks.
• Medium-term (50% Buy): A moderate buy signal suggests some consolidation or choppiness in the intermediate timeframe, though the overall bias remains constructive.
• Long-term (100% Buy): A perfect buy signal reflects strong underlying strength in the longer-term trend, consistent with JNJ's steady climb over the past several months.

Trend Characteristics: The combination of Good strength and Average direction suggests the stock is in a healthy uptrend with solid momentum, though not yet in an overheated or parabolic phase—a supportive backdrop for earnings.

The stock is currently trading at $253.85, above its 20-day ($249.58), 50-day ($237.20), 100-day ($238.05), and 200-day ($221.87) moving averages, confirming the bullish trend across multiple timeframes. However, the stock has pulled back slightly from its 5-day ($258.22) and 10-day ($258.87) moving averages, suggesting some near-term profit-taking or consolidation ahead of the report.

Key resistance now sits near the recent highs around $258 to $260, while support is well-established at the 20-day moving average near $250. The overall technical setup is supportive heading into earnings, with the stock in a confirmed uptrend and holding above all major moving averages. However, the recent pullback from short-term highs suggests some caution among traders, and a disappointing result could see the stock test the 20-day moving average. Conversely, a strong beat and upbeat guidance could propel JNJ toward the high end of the analyst price target range near $298.